These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 23739238)

  • 1. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
    Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
    Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
    Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P; Bonanni A; Ghiggeri GM
    BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K; Sallam HT; Hakim AA; Al-Attiyah R
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):973-8. PubMed ID: 22982909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in children with resistant idiopathic nephrotic syndrome.
    Magnasco A; Ravani P; Edefonti A; Murer L; Ghio L; Belingheri M; Benetti E; Murtas C; Messina G; Massella L; Porcellini MG; Montagna M; Regazzi M; Scolari F; Ghiggeri GM
    J Am Soc Nephrol; 2012 Jun; 23(6):1117-24. PubMed ID: 22581994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
    Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in the treatment of nephrotic syndrome: a systematic review.
    Otukesh H; Hoseini R; Rahimzadeh N; Fazel M
    Iran J Kidney Dis; 2013 Jul; 7(4):249-56. PubMed ID: 23880800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Hodson EM; Wong SC; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotic syndrome: Rituximab in childhood steroid-dependent nephrotic syndrome.
    Boyer O; Niaudet P
    Nat Rev Nephrol; 2013 Oct; 9(10):562-3. PubMed ID: 23938594
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
    Sinha A; Gupta A; Kalaivani M; Hari P; Dinda AK; Bagga A
    Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Liu ID; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
    Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
    Basu B; Mahapatra TK; Mondal N
    Pediatrics; 2015 Jul; 136(1):e132-9. PubMed ID: 26101364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.
    Takahashi T; Okamoto T; Sato Y; Yamazaki T; Hayashi A; Aoyagi H; Ueno M; Kobayashi N; Uetake K; Nakanishi M; Ariga T
    Pediatr Nephrol; 2019 Jan; 34(1):87-96. PubMed ID: 30141179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.